SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-22-018839
Filing Date
2022-05-12
Accepted
2022-05-12 16:23:13
Documents
62
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q brhc10037371_10q.htm   iXBRL 10-Q 1703429
2 EXHIBIT 31.1 brhc10037371_ex31-1.htm EX-31.1 12296
3 EXHIBIT 31.2 brhc10037371_ex31-2.htm EX-31.2 12273
4 EXHIBIT 32.1 brhc10037371_ex32-1.htm EX-32.1 4985
5 EXHIBIT 32.2 brhc10037371_ex32-2.htm EX-32.2 5122
  Complete submission text file 0001140361-22-018839.txt   6320468

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA knte-20220331.xsd EX-101.SCH 35907
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE knte-20220331_cal.xml EX-101.CAL 53518
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE knte-20220331_def.xml EX-101.DEF 174569
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE knte-20220331_lab.xml EX-101.LAB 499105
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE knte-20220331_pre.xml EX-101.PRE 323146
56 EXTRACTED XBRL INSTANCE DOCUMENT brhc10037371_10q_htm.xml XML 941322
Mailing Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130
Business Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130 8582994699
Kinnate Biopharma Inc. (Filer) CIK: 0001797768 (see all company filings)

IRS No.: 824566526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39743 | Film No.: 22918167
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences